Cancer

US regulators fast-track novel leukemia therapy

US regulators on Monday put an experimental immunotherapy agent on the fast track to market approval, after 89 percent of leukemia patients in early trials saw their cancers disappear.

Cancer

Rituximab and fludarabine produce long-term remissions in CLL

New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the ...

Cancer

New immune Tx achieves remission in B-cell malignancies

(HealthDay)—A new T-cell immunotherapy has led to sustained regression in many previously relapsing and treatment-resistant cases of acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, ...

Cardiology

High-value research of 2014 presented for hematology

(HealthDay)—Articles relating to malignant hematology, transfusion medicine, and bleeding and clotting disorders are included in a special update summary published online April 30 in the Annals of Internal Medicine.

Cancer

Modified killer T-cells wipe out leukemia: study

Three US cancer patients were brought back from the brink by a new therapy that turned their own immune cells into tumor killers, wiping out an advanced form of leukemia, researchers said Wednesday.

Cancer

MicroRNA-TP53 circuit connected to chronic lymphocytic leukemia

The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team ...

page 3 from 14